[go: up one dir, main page]

MX2019005450A - Pharmaceutical compositions and methods for the treatment of cancer. - Google Patents

Pharmaceutical compositions and methods for the treatment of cancer.

Info

Publication number
MX2019005450A
MX2019005450A MX2019005450A MX2019005450A MX2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A
Authority
MX
Mexico
Prior art keywords
promoter
methods
subject
pharmaceutical compositions
inhibitor
Prior art date
Application number
MX2019005450A
Other languages
Spanish (es)
Inventor
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of MX2019005450A publication Critical patent/MX2019005450A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)

Abstract

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
MX2019005450A 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer. MX2019005450A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019005450A true MX2019005450A (en) 2019-07-04

Family

ID=60570232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005450A MX2019005450A (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer.

Country Status (12)

Country Link
EP (1) EP3541411A1 (en)
JP (2) JP2019537608A (en)
KR (2) KR20230003314A (en)
CN (1) CN110167580A (en)
AU (1) AU2017361080A1 (en)
BR (1) BR112019009799A2 (en)
CA (1) CA3040922A1 (en)
EA (1) EA201991192A1 (en)
IL (1) IL266486A (en)
MX (1) MX2019005450A (en)
PH (1) PH12019500758A1 (en)
WO (1) WO2018093820A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. Compositions and methods for treating cancer
WO2021076723A1 (en) * 2019-10-15 2021-04-22 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
IL294803A (en) * 2020-01-17 2022-09-01 Tyme Inc A history of tyrosine for cancer modulation
CN111358777A (en) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 A method and application for improving mitochondrial function of peripheral blood mononuclear cells
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
JP2023553011A (en) * 2020-12-02 2023-12-20 ホフマン・テクノロジーズ・エルエルシー Compositions and methods for modulating cancer in non-human mammals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO2006036892A2 (en) * 2004-09-24 2006-04-06 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
NZ628757A (en) * 2012-01-17 2016-07-29 Tyme Inc Pharmaceutical compositions and methods for treating cancer
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
JP2023018029A (en) 2023-02-07
IL266486A (en) 2019-07-31
JP2019537608A (en) 2019-12-26
KR20190084291A (en) 2019-07-16
EP3541411A1 (en) 2019-09-25
BR112019009799A2 (en) 2019-08-06
CA3040922A1 (en) 2018-05-24
AU2017361080A1 (en) 2019-05-02
EA201991192A1 (en) 2019-10-31
WO2018093820A1 (en) 2018-05-24
PH12019500758A1 (en) 2019-07-24
CN110167580A (en) 2019-08-23
KR20230003314A (en) 2023-01-05

Similar Documents

Publication Publication Date Title
PH12014501639B1 (en) Pharmaceutical compositions and methods
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020013649A (en) Compositions and methods for inhibiting arginase activity.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EA201890961A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT NORROFORMATION
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX387885B (en) Ezh2 inhibitors for treating lymphoma
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2017001656A (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof.
EA201890957A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMORS
MX2017010595A (en) Methods, compositions, and kits for treatment of cancer.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2018002344A (en) Method for treating cancer.
MX2018007266A (en) Combinations for the treatment of cancer.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2019013862A (en) Combination therapy.
MX2018012511A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors.
HK1258319A1 (en) Cancer therapy
MX2022002699A (en) Lurbinectedin in the treatment of malignant mesothelioma.
MX2020001727A (en) Combination therapy.
EP4640237A3 (en) Macrophage-based therapy for use in the treatment of acute liver injury